Merus NV to Present Promising Phase 2 Data for Petosemtamab in Metastatic Colorectal Cancer at Major Oncology Conference
Merus N.V. has announced the upcoming presentation of initial interim data from a phase 2 trial evaluating petosemtamab, a bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (mCRC). The data, which assess petosemtamab in combination with standard chemotherapy in first- and second-line mCRC and as monotherapy in heavily pretreated (third-line and beyond) mCRC, will be presented during a plenary session at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The plenary session is scheduled for Friday, October 24, 2025, from 10:00 to 11:40 a.m. ET. Additionally, Merus will present a poster on the preclinical evaluation of petosemtamab on cancer stem cells during Poster Session B, held on the same day from 12:30 to 4:00 p.m. ET. The abstracts will be available in the conference app starting Wednesday, October 22, 2025, at 12:00 p.m. ET, and full presentations are planned for availability on the Merus website at the start of each session.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merus NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9543421-en) on October 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.